- Home
- BRID vs NRXP Comparison
BRID vs NRXP Comparison
Compare BRID & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRID
- NRXP
- Stock Information
- Founded
- BRID 1932
- NRXP 2015
- Country
- BRID United States
- NRXP United States
- Employees
- BRID N/A
- NRXP N/A
- Industry
- BRID Specialty Foods
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- BRID Consumer Staples
- NRXP Health Care
- Exchange
- BRID Nasdaq
- NRXP Nasdaq
- Market Cap
- BRID 72.8M
- NRXP 58.5M
- IPO Year
- BRID N/A
- NRXP N/A
- Fundamental
- Price
- BRID $7.94
- NRXP $3.27
- Analyst Decision
- BRID
- NRXP Strong Buy
- Analyst Count
- BRID 0
- NRXP 5
- Target Price
- BRID N/A
- NRXP $31.40
- AVG Volume (30 Days)
- BRID 3.5K
- NRXP 458.2K
- Earning Date
- BRID 08-22-2025
- NRXP 11-13-2025
- Dividend Yield
- BRID N/A
- NRXP N/A
- EPS Growth
- BRID N/A
- NRXP N/A
- EPS
- BRID N/A
- NRXP N/A
- Revenue
- BRID $224,673,000.00
- NRXP N/A
- Revenue This Year
- BRID N/A
- NRXP N/A
- Revenue Next Year
- BRID N/A
- NRXP $395.09
- P/E Ratio
- BRID N/A
- NRXP N/A
- Revenue Growth
- BRID N/A
- NRXP N/A
- 52 Week Low
- BRID $7.35
- NRXP $1.10
- 52 Week High
- BRID $10.83
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- BRID 52.37
- NRXP 62.11
- Support Level
- BRID $7.76
- NRXP $3.19
- Resistance Level
- BRID $8.24
- NRXP $3.48
- Average True Range (ATR)
- BRID 0.14
- NRXP 0.18
- MACD
- BRID -0.02
- NRXP 0.04
- Stochastic Oscillator
- BRID 45.45
- NRXP 68.66
About BRID Bridgford Foods Corporation
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.